Detailed Instructions: Given a passage classify if the passage has a definite objective/aim/goal or not. Output '1' if the passage has a defininte objective/aim/goal and output '0' if the passage does not have a definite objective/aim/goal.
Q: The objective of this study was to evaluate the effects of abacavir on intracellular ribavirin triphosphate and plasma ribavirin trough concentrations.', 'Hepatitis C virus-infected subjects who had been cured or failed prior treatment were randomized to 8 weeks of ribavirin alone (N=14; weight-based dosing) or weight-based ribavirin+abacavir (N=14; 300 mg orally every 12 h). Ribavirin trough concentrations were measured on days 14, 28, 42 and 56; PBMCs for ribavirin triphosphate determination were sampled on days 28 and 56, pre-dose and at 6 and 12 h post-dose. ClinicalTrials.gov: NCT01052701.', 'Twenty-six subjects completed the study (24 males, 17 Caucasians, median age 52 years); 2 were excluded for missed pharmacokinetic visits. Fourteen subjects received ribavirin+abacavir and 12 received ribavirin alone. MeanSD plasma ribavirin trough concentrations (g/mL) on days 14, 28, 42 and 56, respectively, were not significantly different with coadministration of abacavir (1.540.60, 1.930.54, 2.140.73 and 2.541.05) compared with ribavirin alone (1.480.32, 2.080.41, 2.320.47 and 2.600.62) (P>0.40). Mean ribavirin triphosphate intracellular concentrations (pmol/10(6) cells) on days 28 and 56, respectively, did not differ statistically between abacavir users (11.989.86 and 15.8712.52) and non-users (15.9115.58 and 15.9312.69) (P>0.4). Adverse events were mild or moderate, except for three grade 3 occurrences of transaminitis, cholecystitis and low absolute neutrophil count that resolved and were judged not attributable to study medications.
A:
1